Expression  ||| S:0 E:11 ||| NN
of  ||| S:11 E:14 ||| IN
CD57  ||| S:14 E:19 ||| CD
on  ||| S:19 E:22 ||| IN
CD8+  ||| S:22 E:27 ||| CD
T  ||| S:27 E:29 ||| NN
lymphocytes  ||| S:29 E:41 ||| NN
of  ||| S:41 E:44 ||| IN
patients  ||| S:44 E:53 ||| NNS
with  ||| S:53 E:58 ||| IN
Wegener ||| S:58 E:65 ||| NNP
's  ||| S:65 E:68 ||| POS
granulomatosis  ||| S:68 E:83 ||| NN
and  ||| S:83 E:87 ||| CC
microscopic  ||| S:87 E:99 ||| JJ
polyangiitis ||| S:99 E:111 ||| NN
:  ||| S:111 E:113 ||| :
evidence  ||| S:113 E:122 ||| NN
for  ||| S:122 E:126 ||| IN
continuous  ||| S:126 E:137 ||| JJ
activation  ||| S:137 E:148 ||| NN
of  ||| S:148 E:151 ||| IN
CD8+  ||| S:151 E:156 ||| CD
cells  ||| S:156 E:162 ||| NNS
To  ||| S:162 E:165 ||| TO
gain  ||| S:165 E:170 ||| VB
insight  ||| S:170 E:178 ||| VBN
into  ||| S:178 E:183 ||| IN
the  ||| S:183 E:187 ||| DT
immune  ||| S:187 E:194 ||| JJ
pathogenesis  ||| S:194 E:207 ||| NN
of  ||| S:207 E:210 ||| IN
Wegener ||| S:210 E:217 ||| NNP
's  ||| S:217 E:220 ||| POS
granulomatosis  ||| S:220 E:235 ||| NN
( ||| S:235 E:236 ||| -LRB-
WG ||| S:236 E:238 ||| NNP
)  ||| S:238 E:240 ||| -RRB-
and  ||| S:240 E:244 ||| CC
microscopic  ||| S:244 E:256 ||| JJ
polyangiitis  ||| S:256 E:269 ||| NNS
( ||| S:269 E:270 ||| -LRB-
MPA ||| S:270 E:273 ||| NNP
) ||| S:273 E:274 ||| -RRB-
,  ||| S:274 E:276 ||| ,
the  ||| S:276 E:280 ||| DT
prevalence  ||| S:280 E:291 ||| NN
of  ||| S:291 E:294 ||| IN
circulating  ||| S:294 E:306 ||| VBG
CD8+  ||| S:306 E:311 ||| CD
T  ||| S:311 E:313 ||| NN
lymphocytes  ||| S:313 E:325 ||| VBZ
expressing  ||| S:325 E:336 ||| VBG
CD57  ||| S:336 E:341 ||| NN
as  ||| S:341 E:344 ||| IN
a  ||| S:344 E:346 ||| DT
marker  ||| S:346 E:353 ||| NN
for  ||| S:353 E:357 ||| IN
previous  ||| S:357 E:366 ||| JJ
activation  ||| S:366 E:377 ||| NN
was  ||| S:377 E:381 ||| VBD
analyzed ||| S:381 E:389 ||| VBN
.  ||| S:389 E:391 ||| .
Receptor  ||| S:391 E:400 ||| JJ
expression  ||| S:400 E:411 ||| NN
of  ||| S:411 E:414 ||| IN
CD57  ||| S:414 E:419 ||| NNP
was  ||| S:419 E:423 ||| VBD
measured  ||| S:423 E:432 ||| VBN
in  ||| S:432 E:435 ||| IN
CD8+  ||| S:435 E:440 ||| CD
T  ||| S:440 E:442 ||| NN
cells  ||| S:442 E:448 ||| NNS
of  ||| S:448 E:451 ||| IN
patients  ||| S:451 E:460 ||| NNS
with  ||| S:460 E:465 ||| IN
active  ||| S:465 E:472 ||| JJ
disease  ||| S:472 E:480 ||| NN
( ||| S:480 E:481 ||| -LRB-
n=5 ||| S:481 E:484 ||| NNP
)  ||| S:484 E:486 ||| -RRB-
by  ||| S:486 E:489 ||| IN
cytofluorometry  ||| S:489 E:505 ||| NN
and  ||| S:505 E:509 ||| CC
compared  ||| S:509 E:518 ||| VBN
with  ||| S:518 E:523 ||| IN
expression  ||| S:523 E:534 ||| NN
in  ||| S:534 E:537 ||| IN
patients  ||| S:537 E:546 ||| NNS
in  ||| S:546 E:549 ||| IN
remission  ||| S:549 E:559 ||| NNS
( ||| S:559 E:560 ||| -LRB-
n=80 ||| S:560 E:564 ||| NNP
)  ||| S:564 E:566 ||| -RRB-
and  ||| S:566 E:570 ||| CC
in  ||| S:570 E:573 ||| IN
age-matched  ||| S:573 E:585 ||| JJ
healthy  ||| S:585 E:593 ||| JJ
donors  ||| S:593 E:600 ||| NNS
( ||| S:600 E:601 ||| -LRB-
n=34 ||| S:601 E:605 ||| NNP
) ||| S:605 E:606 ||| -RRB-
.  ||| S:606 E:608 ||| .
The  ||| S:608 E:612 ||| DT
results  ||| S:612 E:620 ||| NNS
were  ||| S:620 E:625 ||| VBD
compared  ||| S:625 E:634 ||| VBN
to  ||| S:634 E:637 ||| TO
clinical  ||| S:637 E:646 ||| JJ
parameters  ||| S:646 E:657 ||| NNS
including  ||| S:657 E:667 ||| VBG
severity  ||| S:667 E:676 ||| NN
and  ||| S:676 E:680 ||| CC
duration  ||| S:680 E:689 ||| NN
of  ||| S:689 E:692 ||| IN
the  ||| S:692 E:696 ||| DT
disease ||| S:696 E:703 ||| NN
.  ||| S:703 E:705 ||| .
CD8+CD57+  ||| S:705 E:715 ||| NNP
were  ||| S:715 E:720 ||| VBD
detected  ||| S:720 E:729 ||| VBN
in  ||| S:729 E:732 ||| IN
patients  ||| S:732 E:741 ||| NNS
with  ||| S:741 E:746 ||| IN
WG  ||| S:746 E:749 ||| NNP
and  ||| S:749 E:753 ||| CC
MPA  ||| S:753 E:757 ||| NNP
and  ||| S:757 E:761 ||| CC
in  ||| S:761 E:764 ||| IN
healthy  ||| S:764 E:772 ||| JJ
donors  ||| S:772 E:779 ||| NNS
as  ||| S:779 E:782 ||| IN
well  ||| S:782 E:787 ||| RB
and  ||| S:787 E:791 ||| CC
increased  ||| S:791 E:801 ||| VBD
considerably  ||| S:801 E:814 ||| RB
with  ||| S:814 E:819 ||| IN
age ||| S:819 E:822 ||| NN
.  ||| S:822 E:824 ||| .
Compared  ||| S:824 E:833 ||| VBN
to  ||| S:833 E:836 ||| TO
age-matched  ||| S:836 E:848 ||| JJ
healthy  ||| S:848 E:856 ||| JJ
donors ||| S:856 E:862 ||| NNS
,  ||| S:862 E:864 ||| ,
the  ||| S:864 E:868 ||| DT
prevalence  ||| S:868 E:879 ||| NN
of  ||| S:879 E:882 ||| IN
CD8+CD57+  ||| S:882 E:892 ||| NNP
was  ||| S:892 E:896 ||| VBD
increased  ||| S:896 E:906 ||| VBN
in  ||| S:906 E:909 ||| IN
the  ||| S:909 E:913 ||| DT
younger  ||| S:913 E:921 ||| JJR
patients  ||| S:921 E:930 ||| NNS
( ||| S:930 E:931 ||| -LRB-
up  ||| S:931 E:934 ||| RB
to  ||| S:934 E:937 ||| TO
40  ||| S:937 E:940 ||| CD
y ||| S:940 E:941 ||| CD
) ||| S:941 E:942 ||| -RRB-
.  ||| S:942 E:944 ||| .
In  ||| S:944 E:947 ||| IN
most  ||| S:947 E:952 ||| JJS
patients  ||| S:952 E:961 ||| NNS
a  ||| S:961 E:963 ||| DT
high  ||| S:963 E:968 ||| JJ
percentage  ||| S:968 E:979 ||| NN
of  ||| S:979 E:982 ||| IN
CD8+CD57+  ||| S:982 E:992 ||| CD
coincided  ||| S:992 E:1002 ||| NN
with  ||| S:1002 E:1007 ||| IN
severe  ||| S:1007 E:1014 ||| JJ
disease  ||| S:1014 E:1022 ||| NN
and  ||| S:1022 E:1026 ||| CC
multiple  ||| S:1026 E:1035 ||| JJ
organ  ||| S:1035 E:1041 ||| NN
involvement ||| S:1041 E:1052 ||| NN
,  ||| S:1052 E:1054 ||| ,
while  ||| S:1054 E:1060 ||| IN
low  ||| S:1060 E:1064 ||| JJ
CD8+CD57+  ||| S:1064 E:1074 ||| CD
percentage  ||| S:1074 E:1085 ||| NN
was  ||| S:1085 E:1089 ||| VBD
seen  ||| S:1089 E:1094 ||| VBN
in  ||| S:1094 E:1097 ||| IN
patients  ||| S:1097 E:1106 ||| NNS
with  ||| S:1106 E:1111 ||| IN
limited  ||| S:1111 E:1119 ||| JJ
disease  ||| S:1119 E:1127 ||| NN
or  ||| S:1127 E:1130 ||| CC
in  ||| S:1130 E:1133 ||| IN
patients  ||| S:1133 E:1142 ||| NNS
in  ||| S:1142 E:1145 ||| IN
complete  ||| S:1145 E:1154 ||| JJ
remission ||| S:1154 E:1163 ||| NN
.  ||| S:1163 E:1165 ||| .
In  ||| S:1165 E:1168 ||| IN
patients  ||| S:1168 E:1177 ||| NNS
with  ||| S:1177 E:1182 ||| IN
smoldering  ||| S:1182 E:1193 ||| JJ
disease ||| S:1193 E:1200 ||| NN
,  ||| S:1200 E:1202 ||| ,
the  ||| S:1202 E:1206 ||| DT
percentage  ||| S:1206 E:1217 ||| NN
of  ||| S:1217 E:1220 ||| IN
CD8+CD57+  ||| S:1220 E:1230 ||| NNP
increased  ||| S:1230 E:1240 ||| VBD
with  ||| S:1240 E:1245 ||| IN
time ||| S:1245 E:1249 ||| NN
.  ||| S:1249 E:1251 ||| .
High  ||| S:1251 E:1256 ||| JJ
numbers  ||| S:1256 E:1264 ||| NNS
of  ||| S:1264 E:1267 ||| IN
CD8+CD57+  ||| S:1267 E:1277 ||| CD
correlated  ||| S:1277 E:1288 ||| NN
with  ||| S:1288 E:1293 ||| IN
low  ||| S:1293 E:1297 ||| JJ
CD4 ||| S:1297 E:1300 ||| NN
: ||| S:1300 E:1301 ||| :
CD8  ||| S:1301 E:1305 ||| CD
ratio ||| S:1305 E:1310 ||| NN
.  ||| S:1310 E:1312 ||| .
In  ||| S:1312 E:1315 ||| IN
patients  ||| S:1315 E:1324 ||| NNS
with  ||| S:1324 E:1329 ||| IN
WG  ||| S:1329 E:1332 ||| NNP
and  ||| S:1332 E:1336 ||| CC
MPA  ||| S:1336 E:1340 ||| NNP
a  ||| S:1340 E:1342 ||| DT
population  ||| S:1342 E:1353 ||| NN
of  ||| S:1353 E:1356 ||| IN
CD8+CD57+  ||| S:1356 E:1366 ||| CD
expand ||| S:1366 E:1372 ||| NN
,  ||| S:1372 E:1374 ||| ,
identifying  ||| S:1374 E:1386 ||| VBG
terminally  ||| S:1386 E:1397 ||| JJ
differentiated  ||| S:1397 E:1412 ||| JJ
CD8+  ||| S:1412 E:1417 ||| CD
cells ||| S:1417 E:1422 ||| NNS
.  ||| S:1422 E:1424 ||| .
The  ||| S:1424 E:1428 ||| DT
prevalence  ||| S:1428 E:1439 ||| NN
of  ||| S:1439 E:1442 ||| IN
CD57+  ||| S:1442 E:1448 ||| CD
cells  ||| S:1448 E:1454 ||| NNS
was  ||| S:1454 E:1458 ||| VBD
related  ||| S:1458 E:1466 ||| VBN
to  ||| S:1466 E:1469 ||| TO
the  ||| S:1469 E:1473 ||| DT
course  ||| S:1473 E:1480 ||| NN
of  ||| S:1480 E:1483 ||| IN
disease ||| S:1483 E:1490 ||| NN
.  ||| S:1490 E:1492 ||| .
So  ||| S:1492 E:1495 ||| RB
far ||| S:1495 E:1498 ||| RB
,  ||| S:1498 E:1500 ||| ,
the  ||| S:1500 E:1504 ||| DT
function  ||| S:1504 E:1513 ||| NN
of  ||| S:1513 E:1516 ||| IN
CD57  ||| S:1516 E:1521 ||| CD
on  ||| S:1521 E:1524 ||| IN
CD8+  ||| S:1524 E:1529 ||| CD
cells  ||| S:1529 E:1535 ||| NNS
is  ||| S:1535 E:1538 ||| VBZ
not  ||| S:1538 E:1542 ||| RB
understood ||| S:1542 E:1552 ||| VBN
.  ||| S:1552 E:1554 ||| .
However ||| S:1554 E:1561 ||| RB
,  ||| S:1561 E:1563 ||| ,
these  ||| S:1563 E:1569 ||| DT
cells  ||| S:1569 E:1575 ||| NNS
might  ||| S:1575 E:1581 ||| MD
produce  ||| S:1581 E:1589 ||| VB
certain  ||| S:1589 E:1597 ||| JJ
cytokines ||| S:1597 E:1606 ||| NN
,  ||| S:1606 E:1608 ||| ,
which  ||| S:1608 E:1614 ||| WDT
play  ||| S:1614 E:1619 ||| VBP
a  ||| S:1619 E:1621 ||| DT
role  ||| S:1621 E:1626 ||| NN
in  ||| S:1626 E:1629 ||| IN
the  ||| S:1629 E:1633 ||| DT
pathogenesis  ||| S:1633 E:1646 ||| NN
of  ||| S:1646 E:1649 ||| IN
AAV ||| S:1649 E:1652 ||| NNP
.  ||| S:1652 E:1654 ||| .
The  ||| S:1654 E:1658 ||| DT
data  ||| S:1658 E:1663 ||| NNS
support  ||| S:1663 E:1671 ||| VBP
the  ||| S:1671 E:1675 ||| DT
hypothesis  ||| S:1675 E:1686 ||| NN
that  ||| S:1686 E:1691 ||| IN
CD8+  ||| S:1691 E:1696 ||| CD
T  ||| S:1696 E:1698 ||| NN
cells  ||| S:1698 E:1704 ||| NNS
are  ||| S:1704 E:1708 ||| VBP
activated  ||| S:1708 E:1718 ||| VBN
in  ||| S:1718 E:1721 ||| IN
the  ||| S:1721 E:1725 ||| DT
context  ||| S:1725 E:1733 ||| NN
of  ||| S:1733 E:1736 ||| IN
primary  ||| S:1736 E:1744 ||| JJ
vasculitides ||| S:1744 E:1756 ||| NN
.  ||| S:1756 E:1758 ||| .
